Display options
Cite
Lim SYD, Cheong EC, Oon HH. Management of severe hidradenitis suppurativa with biologic therapy and wide excision. Arch Plast Surg. 2019;46(3):272-276doi: 10.5999/aps.2018.00339.
Lim, S. Y. D., Cheong, E. C., & Oon, H. H. (2019). Management of severe hidradenitis suppurativa with biologic therapy and wide excision. Archives of plastic surgery, 46(3), 272-276. https://doi.org/10.5999/aps.2018.00339
Lim, Shi Yu Derek, et al. "Management of severe hidradenitis suppurativa with biologic therapy and wide excision." Archives of plastic surgery vol. 46,3 (2019): 272-276. doi: https://doi.org/10.5999/aps.2018.00339
Lim SYD, Cheong EC, Oon HH. Management of severe hidradenitis suppurativa with biologic therapy and wide excision. Arch Plast Surg. 2019 May;46(3):272-276. doi: 10.5999/aps.2018.00339. Epub 2019 Apr 20. PMID: 31006182; PMCID: PMC6536865.
Copy Download .nbib Format: NLM
Share it on

Arch Plast Surg. 2019 May;46(3):272-276. doi: 10.5999/aps.2018.00339. Epub 2019 Apr 20.

Management of severe hidradenitis suppurativa with biologic therapy and wide excision.

Archives of plastic surgery

Shi Yu Derek Lim, Ee Cherk Cheong, Hazel H Oon

Affiliations

  1. National Healthcare Group, Singapore.
  2. Plastic, Reconstructive and Aesthetic Surgery Service, Department of General Surgery, Tan Tock Seng Hospital, Singapore.
  3. National Skin Centre, Singapore.

PMID: 31006182 PMCID: PMC6536865 DOI: 10.5999/aps.2018.00339

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory follicular occlusive disease that involves the intertriginous areas. Treatment methods include conventional topical and systemic medication, radiotherapy, biologic agents, and surgical excision. Of late, there has been an increased focus on the use of biologic agents in patients with moderate to severe HS. Here, we present the case of a 46-year-old man with Hurley stage III HS for whom wide excision was ultimately curative, after aggressive medical therapy with the use of infliximab and adalimumab had succeeded in limiting the body surface area affected by the disease. This case demonstrates the effective treatment of severe HS with a combination of biologic therapy and surgery.

Keywords: Adalimumab; Antibodies, monoclonal; Hidradenitis suppurativa; Infliximab; Tumor necrosis factor-alpha

References

  1. Int J Dermatol. 2005 Jul;44(7):535-40 - PubMed
  2. J Am Acad Dermatol. 2010 Feb;62(2):205-17 - PubMed
  3. J Am Acad Dermatol. 2014 Feb;70(2):243-51 - PubMed
  4. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44 - PubMed
  5. J Am Acad Dermatol. 2015 Sep;73(3):420-8.e1 - PubMed
  6. J Eur Acad Dermatol Venereol. 2016 Jun;30(6):989-94 - PubMed
  7. JAMA Dermatol. 2016 Jan;152(1):52-59 - PubMed
  8. Br J Dermatol. 2016 Apr;174(4):839-46 - PubMed
  9. Rev Endocr Metab Disord. 2016 Sep;17(3):343-351 - PubMed
  10. N Engl J Med. 2016 Aug 4;375(5):422-34 - PubMed
  11. JAMA Dermatol. 2017 Nov 1;153(11):1195-1197 - PubMed
  12. Expert Opin Investig Drugs. 2018 Jan;27(1):43-53 - PubMed
  13. J Clin Aesthet Dermatol. 2017 Sep;10(9):36-38 - PubMed
  14. J Am Acad Dermatol. 2019 Jan;80(1):60-69.e2 - PubMed
  15. Clin Exp Dermatol. 1994 May;19(3):210-6 - PubMed

Publication Types